Parkman Healthcare Partners LLC Makes New $4.11 Million Investment in OptimizeRx Corp. $OPRX

Key Points

• Parkman Healthcare Partners LLC acquired 475,000 shares of OptimizeRx Corp. valued at approximately $4.1 million, now owning around 2.57% of the company.
• OptimizeRx's stock has displayed significant growth, with a 52-week low of $3.78 and a high of $19.25, currently opening at $18.82.
• Equities research analysts have shown positive sentiment towards OptimizeRx, with multiple firms upgrading their ratings to "buy" and raising price targets, indicating confidence in the company’s future performance.

Parkman Healthcare Partners LLC acquired a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 475,000 shares of the company's stock, valued at approximately $4,114,000. Parkman Healthcare Partners LLC owned approximately 2.57% of OptimizeRx at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in OptimizeRx in the 1st quarter valued at $33,000. Wells Fargo & Company MN increased its stake in shares of OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the last quarter. Graham Capital Management L.P. bought a new position in shares of OptimizeRx in the 4th quarter valued at $81,000. MetLife Investment Management LLC bought a new position in shares of OptimizeRx in the 1st quarter valued at $99,000. Finally, BNP Paribas Financial Markets increased its stake in shares of OptimizeRx by 504.6% in the 4th quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock valued at $108,000 after purchasing an additional 18,618 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Price Performance

Shares of NASDAQ OPRX traded down $0.50 during mid-day trading on Tuesday, hitting $17.79. 243,350 shares of the stock traded hands, compared to its average volume of 342,266. OptimizeRx Corp. has a twelve month low of $3.78 and a twelve month high of $19.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The company has a market cap of $330.27 million, a PE ratio of -32.94 and a beta of 1.20. The firm has a 50 day simple moving average of $15.09 and a two-hundred day simple moving average of $11.61.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on OPRX shares. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Stifel Nicolaus lifted their price target on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Zacks Research upgraded OptimizeRx from a "hold" rating to a "strong-buy" rating in a research note on Friday. Finally, JMP Securities lifted their price target on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.